Actively Recruiting
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Led by Johnson & Johnson Enterprise Innovation Inc. · Updated on 2026-05-08
126
Participants Needed
15
Research Sites
288 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
CONDITIONS
Official Title
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
- For Part 1: NSCLC with a known actionable genetic mutation must have received all approved targeted therapies and have progressed
- For Part 2: No targetable mutations (e.g., EGFR, ALK, ROS1, BRAF)
- Part 1 and Cohort A of Part 2: Must have been treated with anti-PD-1 or PD-L1 therapy and platinum-based chemotherapy
- Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as prior therapy
- Cohort C of Part 2: Treatment naive
- Adequate organ function
You will not qualify if you...
- Active central nervous system (CNS) disease involvement
- Active autoimmune disease
- Active infection
- History of solid organ or hematologic stem cell transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
City of Hope 1
Newnan, Georgia, United States, 30265
Actively Recruiting
2
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
3
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States, 14203
Actively Recruiting
4
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
New York, New York, United States, 10032
Actively Recruiting
5
Providence Portland Medical Center
Portland, Oregon, United States, 97213
Actively Recruiting
6
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
7
Next Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
8
Charite Research Organisation GmbH
Berlin, Germany, 12203
Completed
9
Universitaetsklinikum Giessen und Marburg GmbH
Giessen, Germany, 35392
Actively Recruiting
10
Severance Hospital Yonsei University Health System
Seoul, South Korea, 03722
Actively Recruiting
11
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
12
Hosp. Univ. Quiron Dexeus
Barcelona, Spain, 08028
Actively Recruiting
13
Hosp Univ Vall D Hebron
Barcelona, Spain, 8035
Actively Recruiting
14
Hosp. Univ. 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
15
Hosp. Univ. I Politecni La Fe
Valencia, Spain, 46026
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here